Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction

被引:198
作者
Askari, AT
Brennan, ML
Zhou, XR
Drinko, J
Morehead, A
Thomas, JD
Topol, EJ
Hazen, SL
Penn, MS
机构
[1] Cleveland Clin Fdn, Expt Anim Lab, Dept Cardiovasc Med, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA
[3] Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA
关键词
myocardial rupture; free radical; chlorination; inflammation; protease activation;
D O I
10.1084/jem.20021426
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Left ventricular (LV) remodeling after myocardial infarction (MI) results in LV dilation, a major cause of congestive heart failure and sudden cardiac death. Ischemic injury and the ensuing inflammatory response participate in LV remodeling, leading to myocardial rupture and LV dilation. Myeloperoxidase (MPO), which accumulates in the infarct zone, is released from neutrophils and monocytes leading to the formation of reactive chlorinating species capable of oxidizing proteins and altering biological function. We studied acute myocardial infarction (AMI) in a chronic coronary artery ligation model in NIPO null mice (MPO-/-). MPO-/- demonstrated decreased leukocyte infiltration, significant reduction in LV dilation, and marked preservation of LV function. The mechanism appears to be due to decreased oxidative inactivation of plasminogen activator inhibitor I (PAI-1) in the MPO-/-, leading to decreased tissue plasmin activity. MPO and PAI-1 are shown to have a critical role in the LV response immediately after MI, as demonstrated by markedly delayed myocardial rupture in the MPO-/- and accelerated rupture in the PAI-1(-/-). These data offer a mechanistic link between inflammation and LV remodeling by demonstrating a heretofore unrecognized role for MPO and PAI-1 in orchestrating the myocardial response to AMI.
引用
收藏
页码:615 / 624
页数:10
相关论文
共 41 条
[21]   INACTIVATION OF PLASMINOGEN-ACTIVATOR INHIBITOR BY OXIDANTS [J].
LAWRENCE, DA ;
LOSKUTOFF, DJ .
BIOCHEMISTRY, 1986, 25 (21) :6351-6355
[22]   Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes [J].
Lijnen, HR ;
Van Hoef, B ;
Lupu, F ;
Moons, L ;
Carmeliet, P ;
Collen, D .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (07) :1035-1045
[23]  
Lowey OH, 1951, J BIOL CHEM, V193, P265
[24]   Angiotensin II and IV stimulate expression and release of plasminogen activator inhibitor-1 in cultured human coronary artery endothelial cells [J].
Mehta, JL ;
Li, DY ;
Yang, H ;
Raizada, MK .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2002, 39 (06) :789-794
[25]   A truncated plasminogen activator inhibitor-1 protein induces and inhibits angiostatin (kringles 1-3), a plasminogen cleavage product [J].
Mulligan-Kehoe, MJ ;
Wagner, R ;
Wieland, C ;
Powell, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (11) :8588-8596
[26]   A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians [J].
Nikpoor, B ;
Turecki, G ;
Fournier, C ;
Théroux, P ;
Rouleau, GA .
AMERICAN HEART JOURNAL, 2001, 142 (02) :336-339
[27]  
Nishimura H, 1997, THROMB HAEMOSTASIS, V77, P1189
[28]   Fosinopril versus amlodipine comparative treatments study - A randomized trial to assess effects on plasminogen activator inhibitor-1 [J].
Pahor, M ;
Franse, LV ;
Deitcher, SR ;
Cushman, WC ;
Johnson, KC ;
Shorr, RI ;
Kottke-Marchant, K ;
Tracy, RP ;
Somes, GW ;
Applegate, WB .
CIRCULATION, 2002, 105 (04) :457-461
[29]   Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition [J].
Pinsky, DJ ;
Liao, H ;
Lawson, CA ;
Yan, SF ;
Chen, JX ;
Carmeliet, P ;
Loskutoff, DJ ;
Stern, DM .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (05) :919-928
[30]   Influence of prior ACE inhibitor therapy on morbidity and mortality following acute myocardial infarction [J].
Raggi, P ;
Dickson, NR ;
Boyne, M ;
Pereira, R ;
Cooil, B ;
Wattanasuwan, N ;
Russell, DC .
ANNALS OF PHARMACOTHERAPY, 1998, 32 (11) :1141-1146